Anand Patel, CMO, of Conquest Research and a Principal Investigator Shares Insights from the Significant Benefits of LX9211

Shots: Anand briefed PharmaShots about the study design and the results from the RELIEF-DPN-1 trial of its investigational drug LX9211 presented at the 16th Annual Pain Therapeutics Summit He spoke about how LX9211 met its primary endpoints and how the drug shows considerable promise as a novel therapeutic medication for the treatment of painful diabetic…